| ABSTRACT TITLE | FIRST AUTHOR | ABSTRACT NO. |
| The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC). 予測因子・局所進行 | R. T. Shroff | 4500 |
| A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).進行膵癌 | H. L. Kindler | 4501 |
| A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas— GOIM/GISCAD/GOIRC) study.進行膵癌 | G. Colucci | 4504 |
| ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. 術後補助 | J. Neoptolemos | LBA4505 |
| A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. 進行膵癌 | H. Riess | LBA4506 |
| SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. 進行膵癌 | D. D. Von Hoff | 4525 |
| Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial.進行膵癌 | M. Loehr | 4526 |
| Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: Updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203).術後補助 | J. L. Van Laethem | 4527 |
| Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development. 研究 | M. Hidalgo | 4528 |
| Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. 研究・進行膵癌 | D. Laheru | 4529 |
| Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): Results from a genome-wide association study (GWAS) in CALGB 80303. 遺伝子研究 | F. Innocenti | 4531 |
| Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. 進行膵癌（＊） | C. Verslype | 4532 |
| A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC).進行膵癌 | T. Buanes | 4601 |
| Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.切除不能 | E. Ben-Josef | 4602 |
| Use of amolecular mimicry approach to identify effective agents in pancreatic cancer. 治療効果予測 | A. Tan | 4603 |
| Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine: Interim toxicity analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). 進行膵癌 | V. Heinemann | 4604 |
| Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS).局所進行（＊） | K. J. Chang | 4605 |
| A phase II trial of gemcitabine, docetaxel, and bevacizumab (GDB) in metastatic pancreas cancer.（進行膵癌） | V. J. Picozzi | 4606 |
| A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research.（進行膵癌） | D. Oh | 4607 |
| A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. 術後補助 | M. Reni | 4608 |
| Phase II trial of erlotinib in advanced pancreatic cancer (PC). 進行膵癌 | P. Tang | 4609 |
| Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment of patients with locally advanced, nonmetastatic pancreatic cancer. 局所進行 | R. Wilkowski | 4610 |
| Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. 遺伝子・治療効果予測（進行膵癌） | H. Ueno | 4611 |
| Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine. 進行膵癌（＊） | I. Garrido-Laguna | 4612 |
| Detection of early-stage pancreatic carcinoma. 早期発見 | D. Gold | 4613 |
| A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. 進行膵癌（4剤） | S. Cereda | 4614 |
| Identification of prognostic factors for patients with advanced pancreatic cancer by proteomics. 進行膵癌（予後予測因子） | J. Matsubara | 4615 |
| GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). 進行膵癌 | D. Goldstein | 4616 |
| Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. 進行膵癌 | P. Hammel | 4617 |
| A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. 進行膵癌（2ndLine） | J. Y. Hwang | 4618 |
| Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. 新薬治験 | H. Oettle | 4619 |
| Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. 進行膵癌・放射線免疫療法 | K. Pennington | 4620 |
| Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. 進行膵癌 | M. M. Javle | 4621 |
| Effects of adjuvant intra-operative radiation therapy after curative resection in pancreatic cancer patients : Results of a randomized study by 11 institutions in Japan. 術後補助 | T. Kinoshita | 4622 |
| Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. 進行膵癌 | R. L. Fine | 4623 |
| Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. 研究 | A. S. Ho | 4624 |
| A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.局所進行 | F. Viret | 4625 |
| Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology. 腫瘍マーカー | A. Marten | 4626 |
| E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis. 局所進行 | H. R. Cardenes | 4627 |
| Salivary biomarkers for pancreatic cancer detection. 腫瘍マーカー | D. T. Wong | 4630 |
| A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.進行膵癌（2ndLine） | H. E. Uronis | e15506 |
| A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC). 進行膵癌 | M. W. Saif | e15508 |
| A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma. 局所進行 | T. Ioka | e15512 |
| Plasma IL-6 level and survival of pancreatic cancer patients treated with a VEGFR inhibitor, vatalanib (PTK/ZK). OS予測因子 | A. F. Baker | e15514 |
| Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer. 進行膵癌 | G. Tonini | e15530 |
| Phase I study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. 術前補助 | T. Hong | e15536 |
| Clinical role of regulatory T cell in intraductal papillary mucinous neoplasms. IPMN免疫 | Y. Morine | e15537 |
| Phase I dose escalation study of pomalidomide in combination with gemcitabine in patients (pts) with untreated metastatic carcinoma of the pancreas. 進行膵癌 | J. R. Infante | e15539 |
| Application of a time-varying covariate model to the analysis of CA 19-9 as a biomarker for time-to-progression (TTP) and overall survival (OS) in patients with advanced pancreatic cancer.腫瘍マーカー | S. Boeck | e15545 |
| Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA). 術前療法 | J. Lee | e15553 |
| Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. 局所進行 | S. Yi | e15558 |
| Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). 進行膵癌(2ndLine) | J. Gasent Blesa | e15561 |
| A phase II study of gemcitabine-based chemoradiotherapy (CCRT) after triplet induction chemotherapy (ICT) for locally advanced pancreatic cancer (LAPC): A Taiwan Cooperative Oncology Group (TCOG) study. 局所進行 | H. Ch'ang | e15562 |
| A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer. 進行膵癌 | N. C. Dhani | e15565 |
| Pretreatment serum TIMP-1 levels and survival in advanced pancreatic cancer. 進行膵癌 | R. Vargas | e15568 |
| A phase II trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent external-beam radiotherapy for locally advanced pancreatic cancer. 局所進行 | H. Shinchi | e15570 |
| Safety and efficacy of single-day GemOx (S-GemOx) regimen in pts with pancreatobiliary cancer (PBC). 局所進行 | M. Y. Merl | e15577 |
| Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.局所進行 | H. Ishii | e15578 |
| Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). 進行膵癌 | L. Dahan | e15583 |
| Association of gender, age, and ethnicity with survival in patients with pancreas cancer. 予後予測因子 | M. Ottochian | e15587 |
| Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer. 進行膵癌(1stLine) | D. J. Cohen | e15594 |
| Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma. 進行膵癌（2ndLine） | M. Mazzer | e15597 |
| A pilot phase I/II study of combination chemotherapy with nafamostat mesilate and gemcitabine for unresectable pancreatic cancer. 切除不能 | T. Uwagawa | e15600 |
| BRSK2 expression as a prognosis marker in pancreatic cancer patients. 予後因子 | W. Lou | e15603 |
| Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods. 遺伝子 | S. Thieltges | e15609 |
| KRAS mutations and relation to prognosis in patients operated for localized pancreatic cancer and other periampullary cancers. 予後因子・局所進行 | N. A. Schultz | e15618 |
| The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. 進行膵癌 | M. Ueno | e15629 |
| A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer.進行膵癌（2ndLine） | M. J. Moore | e15634 |
| The predictive role of CA 19-9 kinetics for time-to-progression (TTP) and overall survival (OS) in patients receiving palliative first-line chemotherapy for advanced pancreatic cancer. 予後予測 | M. Haas | e15637 |
| Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC). 研究 | G. Brandi | e15645 |
| The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study. 進行膵癌(2ndLine) | Y. Nakai | e15648 |
| Case study of a flexible bayesian design in a phase II study in patients with resected pancreas cancer. 臨床研究 | F. E. Harrell | e15651 |
| Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinical results of a clinical phase I trial. 免疫療法 | D. Jin | e15652 |
| Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study. 進行膵癌 | H. Safran | e15653 |
| Prognostic relevance of ribonucleotide reductase small subunit p53R2 in pancreatic cancer 予後因子 | V. M. Chung | e15655 |
| Use of fermented mistletoe (viscum album L.) extract from oak tree (quercus) as supportive treatment for patients with pancreatic cancer. 補助療法 | G. M. Stauder | e15656 |
| Assessment of prognostic factors in pancreatic ductal adenocarcinoma: Focus on the retroperitoneal margin. 予後因子 | A. M. Bellizzi | e15670 |
| Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. 術前補助 | D. Maximous | e15677 |
| Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas. 心のケア | D. Brown | e15678 |
| Diagnostic yield of nonfunctional pancreatic neuroendocrine tumor using endoscopic ultrasound-guided fine needle aspiration biopsy. 内分泌腫瘍 | K. Matsumoto | e15680 |
